Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Does BioCryst gets flu-drug contract from US govt, shares rise?”

0
Posted

Does BioCryst gets flu-drug contract from US govt, shares rise?”

0

Nov 5 (Reuters) – BioCryst Pharmaceuticals Inc said it received an initial order for 10,000 courses of its intravenous flu drug peramivir, valued at $22.5 million, under a contract from the Department of Health and Human Services (HHS), sending its shares up 5 percent. BioCryst said it shipped the entire order from its existing inventory of the drug to the HHS on Nov. 4. ‘We expect to complete production of about 120,000 additional courses of intravenous peramivir by the end of December, and we are prepared to produce more if required to meet orders for the United States or other governments,’ Chief Executive Jon Stonehouse said in a statement. Under the indefinite delivery indefinite quantity contract issued to BioCryst on Nov. 3, HHS may place additional orders for peramivir up to a total of 40,000 courses at the same unit price as the first order, the company said. BioCryst is also required to maintain the ability to manufacture additional treatment courses dependent on the volume a

0

Nov 5 (Reuters) – BioCryst Pharmaceuticals Inc said it received an initial order for 10,000 courses of its intravenous flu drug peramivir, valued at $22.5 million, under a contract from the Department of Health and Human Services (HHS), sending its shares up 5 percent. BioCryst said it shipped the entire order from its existing inventory of the drug to the HHS on Nov. 4. ‘We expect to complete production of about 120,000 additional courses of intravenous peramivir by the end of December, and we are prepared to produce more if required to meet orders for the United States or other governments,’ Chief Executive Jon Stonehouse said in a statement. Under the indefinite delivery indefinite quantity contract issued to BioCryst on Nov. 3, HHS may place additional orders for peramivir up to a total of 40,000 courses at the same unit price as the first order, the company said. BioCryst is also required to maintain the ability to manufacture additional treatment courses dependent on the volume a

Related Questions

What is your question?

*Sadly, we had to bring back ads too. Hopefully more targeted.